Ken Griffin Insmed Inc Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Insmed Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 195,000 shares of INSM stock, worth $15.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

195,000

Previous 81,600 138.97%

Holding current value

$15.5 Million

Previous $5.96 Million 126.02%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$66.29 - $76.63 $850,301 - $982,933	-12,827 Reduced 3.81%	323,735 $22.4 Million
Q3 2024 Nov 14, 2024	SELL	$62.0 - $79.01 $28.7 Million - $36.6 Million	-463,184 Reduced 57.92%	336,562 $24.6 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $2.81 Million - $8.91 Million	-127,817 Reduced 13.78%	799,746 $53.6 Million
Q1 2024 May 15, 2024	SELL	$25.72 - $29.94 $3.05 Million - $3.55 Million	-118,651 Reduced 11.34%	927,563 $25.2 Million
Q4 2023 Feb 14, 2024	BUY	$23.42 - $31.74 $10.9 Million - $14.8 Million	466,832 Added 80.57%	1,046,214 $32.4 Million
Q3 2023 Nov 14, 2023	BUY	$19.86 - $26.93 $3.95 Million - $5.36 Million	199,090 Added 52.35%	579,382 $14.6 Million
Q2 2023 Aug 14, 2023	SELL	$16.44 - $21.1 $10.4 Million - $13.3 Million	-631,910 Reduced 62.43%	380,292 $8.02 Million
Q1 2023 May 15, 2023	BUY	$16.26 - $21.73 $7.91 Million - $10.6 Million	486,609 Added 92.58%	1,012,202 $17.3 Million
Q4 2022 Feb 14, 2023	BUY	$16.98 - $23.15 $2.68 Million - $3.65 Million	157,778 Added 42.9%	525,593 $10.5 Million
Q3 2022 Nov 14, 2022	BUY	$20.88 - $28.21 $2.19 Million - $2.96 Million	105,015 Added 39.96%	367,815 $7.92 Million
Q2 2022 Aug 15, 2022	BUY	$17.07 - $25.71 $1.85 Million - $2.79 Million	108,512 Added 70.33%	262,800 $5.18 Million
Q1 2022 May 16, 2022	BUY	$20.42 - $28.13 $2.92 Million - $4.02 Million	142,907 Added 1255.66%	154,288 $3.63 Million
Q4 2021 Feb 14, 2022	SELL	$25.89 - $33.45 $17.6 Million - $22.7 Million	-679,383 Reduced 98.35%	11,381 $310,000
Q2 2021 Aug 16, 2021	BUY	$24.17 - $36.01 $10.7 Million - $15.9 Million	440,661 Added 176.19%	690,764 $19.7 Million
Q1 2021 May 17, 2021	SELL	$32.28 - $44.3 $30.1 Million - $41.4 Million	-933,496 Reduced 78.87%	250,103 $8.52 Million
Q4 2020 Feb 16, 2021	SELL	$31.45 - $40.54 $28.2 Million - $36.3 Million	-896,175 Reduced 43.09%	1,183,599 $39.4 Million
Q3 2020 Nov 16, 2020	SELL	$26.0 - $34.5 $5.58 Million - $7.4 Million	-214,536 Reduced 9.35%	2,079,774 $66.8 Million
Q2 2020 Aug 14, 2020	SELL	$14.11 - $29.42 $12.5 Million - $26 Million	-884,031 Reduced 27.81%	2,294,310 $63.2 Million
Q1 2020 May 15, 2020	BUY	$13.63 - $33.98 $7.53 Million - $18.8 Million	552,566 Added 21.04%	3,178,341 $50.9 Million
Q4 2019 Feb 14, 2020	SELL	$16.12 - $24.98 $7.05 Million - $10.9 Million	-437,247 Reduced 14.28%	2,625,775 $62.7 Million
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $11.5 Million - $19.1 Million	740,908 Added 31.91%	3,063,022 $54 Million
Q2 2019 Aug 14, 2019	BUY	$23.0 - $32.19 $27.1 Million - $37.9 Million	1,176,356 Added 102.67%	2,322,114 $59.4 Million
Q1 2019 May 15, 2019	BUY	$13.91 - $31.15 $1.08 Million - $2.42 Million	77,755 Added 7.28%	1,145,758 $0
Q4 2018 Feb 14, 2019	BUY	$11.6 - $18.7 $10.8 Million - $17.4 Million	930,003 Added 673.92%	1,068,003 $14 Million
Q3 2018 Nov 13, 2018	SELL	$18.95 - $28.08 $1.6 Million - $2.37 Million	-84,388 Reduced 37.95%	138,000 $0
Q2 2018 Aug 10, 2018	SELL	$20.0 - $29.72 $3.69 Million - $5.48 Million	-184,299 Reduced 45.32%	222,388 $0
Q3 2017 Nov 09, 2017	BUY	$11.61 - $31.21 $4.72 Million - $12.7 Million	406,687	406,687 $12.7 Million

Others Institutions Holding INSM

# of Institutions

490

Shares Held

188M

Call Options Held

3.04M

Put Options Held

3.15M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10.7B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account